Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD) Revenue and Competitors

Miami, FL USA

Location

N/A

Total Funding

Education

Industry

Estimated Revenue & Valuation

  • Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)'s estimated annual revenue is currently $14.2M per year.(i)
  • Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)'s estimated revenue per employee is $180,000

Employee Data

  • Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD) has 79 Employees.(i)
  • Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD) grew their employee count by 72% last year.

Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)'s People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.5M389%N/AN/A
#2
$17.6M981%N/AN/A
#3
$13.7M7636%N/AN/A
#4
$5.9M415%N/AN/A
#5
$8.3M519%N/AN/A
#6
$8.4M524%N/AN/A
#7
$6.9M4871%N/AN/A
#8
$81.5M3625%N/AN/A
#9
$1.8M17-26%N/AN/A
#10
$3.7M290%N/AN/A
Add Company

What Is Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)?

Our mission at Nova Southeastern University’s Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD) is advancing human health through innovation in medical education, research, patient care and community engagement. We will achieve it utilizing a patient-centered, student-centered and community-centered approach.\n\nNSU MD received full accreditation from the Liaison Committee on Medical Education (LCME) on February 16, 2023. This makes NSU MD the nation’s newest—and Florida’s eighth—fully accredited MD college.

keywords:N/A

N/A

Total Funding

79

Number of Employees

$14.2M

Revenue (est)

72%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.8M7939%N/A
#2
$26.1M797%N/A
#3
$27.9M79-16%N/A
#4
$11.5M79-14%N/A
#5
$16.6M7913%N/A